Peptides Emerge as Programmable Molecular Scaffolds Through Advanced Engineering and Synthesis

Peptide therapeutics occupy a unique chemical space, bridging small molecules and biologics with high target specificity and favorable safety profiles. Historically, challenges like inherent lability, poor bioavailability, and rapid degradation have limited their widespread clinical application. This review addresses the critical gap in understanding how recent technological advancements are systematically overcoming these limitations, repositioning peptides as a versatile and powerful class of functional molecules for diverse therapeutic applications, moving beyond their traditional role as simple ligands or hormones.

This comprehensive review systematically surveys the technological advances enabling programmable peptide engineering across the entire discovery-to-development pipeline. It first discusses innovations in chemical synthesis, including automated flow synthesis, chemoselective ligation, noncanonical residue incorporation, backbone editing, conformational constraint, and late-stage functionalization. The review then examines modern discovery approaches such as phage display and mRNA display with the RaPID system, alongside computational and AI-enabled design strategies. It also covers biophysical characterization techniques, cellular target engagement assays, and emerging delivery strategies, concluding with an analysis of translational barriers and successful clinical applications.

The review highlights that collective technological advancements have fundamentally transformed peptide chemistry from simple linear sequence assembly into a modular engineering scaffold. Innovations in synthesis, such as noncanonical residue incorporation and backbone editing, enable precise control over peptide structure and function. Modern discovery platforms, including phage display and AI-enabled design, significantly accelerate hit identification and multi-parameter optimization. Biophysical characterization and advanced delivery strategies are crucial for bridging biochemical potency with intracellular activity. The authors conclude that these advances establish a new era:

Peptides are no longer viewed as inherently labile biomolecules but as chemically programmable scaffolds whose structures and functions can be precisely engineered for therapeutic benefit. This paradigm shift is overcoming traditional translational barriers, paving the way for successful clinical applications.